3′-Deoxyuridine

3′-Deoxyuridine is a dehydroxylated derivative of uridine (Item No. 20300).¹ It inhibits T. gondii uridine phosphorylase (apparent K_i = 2.459 mM). 3′-Deoxyuridine decreases the proliferation of CCRF CEM and L1210 human leukemia, P388 mouse leukemia, and S180 mouse sarcoma cells (EC₅₀s = 25, 5, 2.5, and 15 µM, respectively).² It reduces the infection rate and number of T. cruzi amastigotes in HeLa cells when used at a concentration of 1 µM.³ 3′-Deoxyuridine (500 µM) is less effective than 2′-deoxyuridine (Item No. 27803) at inducing sodium currents in X. laevis oocytes expressing human concentrative nucleoside transporter 1 (CNT 1) or CNT 3.⁴

WARNING This product is not for human or veterinary use.

1. el Kouni, M.H., Naguib, F.N., Panzica, R.P., et al. Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii. Biochem. Pharmacol. 51(12), 1687-1700 (1996).

2. Lin, T.-S., Yang, Y.-H., Liu, M.-C., et al. Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogues and crystal structure of 1-(3-deoxy-β-D-threo-pentofuranosyl)cytosine. J. Med. Chem. 34(2), 693-701 (1991).

3. Nakajima-Shimada, J., Hirota, Y., and Aoki, T. Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Antimicrob. Agents Chemother. 40(11), 2455-2458 (1996).

4. Zhang, J., Smith, K.M., Tackaberry, T., et al. Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol. Pharmacol. 68(3), 830-839 (2005).